Find, compare & contact
Flutemetamol (18F)
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Flutemetamol (18F) API 765922-62-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Flutemetamol (18F). You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Flutemetamol (18F)
- Synonyms:
- [18F]-Flutemetamol , 2-[3-(18F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol , Flutemetamol F 18 , Flutemetamol F-18 , Flutemetamol F18
- Cas Number:
- 765922-62-1
- DrugBank number:
- DB09151
- Unique Ingredient Identifier:
- L49M066S0O
General Description:
Flutemetamol (18F), identified by CAS number 765922-62-1, is a notable compound with significant therapeutic applications. Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Indications:
This drug is primarily indicated for: Flutemetamol F18 is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Flutemetamol (18F) undergoes metabolic processing primarily in: The F 18 in circulation during the 30-120 minutes imaging window in plasma was principally associated with flutemetamol metabolites. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Flutemetamol (18F) are crucial for its therapeutic efficacy: The time-activity curves for flutemetamol F 18 in the brain of subjects with positive scans shows continual signal increases from time zero through 30 minutes post administration, with stable values thereafter up to at least 120 minutes post-injection. Following intravenous injection of 185 MBq (5 mCi) of Vizamyl in humans, flutemetamol F 18 plasma concentrations declined by approximately 75% in the first 20 minutes post-injection, and by approximately 90% in the first 180 minutes. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Route of Elimination:
The elimination of Flutemetamol (18F) from the body primarily occurs through: Excretion was found to be approximately 37% renal and 52% hepatobiliary. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Pharmacodynamics:
Flutemetamol (18F) exerts its therapeutic effects through: Following intravenous injection, flutemetamol F 18 diffuses across the human blood-brain barrier and produces a radioactivity signal detectable throughout the brain. Subsequently, cerebral perfusion decreases the brain flutemetamol F 18 content, with differential retention of the drug in cortical areas that contain β-amyloid aggregates compared to areas that lack the aggregates. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Flutemetamol (18F) functions by: Fluorine-18 (F 18) is a cyclotron-produced radionuclide that decays by positron emission (β+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen-18 with a physical half-life of 109.8 minutes. The positron can undergo annihilation with an electron to produce two gamma rays; the energy of each gamma ray is 511 keV. After flumetamol F18 is given intravenously, it accumulates in beta amyloid plaques in the brain, and thus becomes visible via positron emission tomography (PET). This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Flutemetamol (18F) belongs to the class of organic compounds known as benzothiazoles. These are organic compounds containing a benzene fused to a thiazole ring (a five-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom), classified under the direct parent group Benzothiazoles. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Benzothiazoles class, specifically within the None subclass.
Categories:
Flutemetamol (18F) is categorized under the following therapeutic classes: Amines, Central Nervous System, Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Radiopharmaceuticals, Diagnostic Uses of Chemicals, Heterocyclic Compounds, Fused-Ring, Indicators and Reagents, Laboratory Chemicals, Radioactive Diagnostic Agent, Radiopharmaceutical Activity, Radiopharmaceuticals, Sulfur Compounds, Thiazoles. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Flutemetamol (18F) is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
